In Virtus and Monash IVF claim to deliver, we recommended a mini-portfolio of this pair of ‘assisted reproduction’ companies. Both companies’ share prices took a tumble after their annual meetings this week, Monash IVF is down 15% since that review and Virtus Health 8%. So is this the ‘industry setback’ we referred to which ‘might offer the chance to increase your exposure’?
No. It’s simply a short-term blip spurred by softer than expected industry figures. The larger risks of a change to government funding or sustained pricing pressure from the entry of Primary Health Care into the market remain.